Clinical Trials Browser

Lymphoma, Large B-Cell, Diffuse × Brentuximab Vedotin × 90 days × Clear all

NCT04404283 2026-03-17

ECHELON-3

Phase 3 Active not recruiting

238 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse